MS Brown, JL Goldstein - Science, 1986 - nobelprize.virtual.museum In 1901 a physician, Archibald Garrod, observed a patient with black urine. He used this simple
observation to demonstrate that a single mutant gene can produce a discrete block in a biochemical
pathway, which he called an “inborn error of metabolism”. Garrod's brilliant insight ... Cited by 3285 - Related articles - View as HTML - All 17 versions
L Goldman, MC Weinstein, PA Goldman, LW Williams - JAMA, 1991 - Am Med Assoc To determine the cost-effectiveness of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase
inhibitors (such as lovastatin) for the primary and secondary prevention of coronary heart
disease, we used the Coronary Heart Disease Policy Model, a computer-stimulated ... Cited by 329 - Related articles - All 3 versions
- ►nih.gov [PDF] DR Illingworth, GJ Sexton - Journal of Clinical Investigation, 1984 - pubmedcentral.nih.gov This work was presented in part at the 56th Scientific Meeting of the American Heart
Association, Anaheim, CA, 1983, and was published in abstract (1983. Circulation.
68:111-188). Ad4ress correspondence to Dr. Illingworth, The Oregon Health Sciences ... Cited by 93 - Related articles - All 7 versions
M Mol, JA Leuven, DW Erkelens, TA Schouten, AFH … - The Lancet, 1986 - Elsevier The effects of synvinolin (MK-733), a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme
A reductase, were investigated in 43 patients with heterozygous familial hypercholesterolaemia
in a double-blind, placebo-controlled, dose-finding study. Synvinolin was given in doses ... Cited by 88 - Related articles - All 6 versions
GL Vega, SM Grundy - JAMA, 1987 - Am Med Assoc The introduction of inhibitors of cholesterol biosynthesis offers a new approach to treatment of
hypercholesterolemia. One such agent, lovastatin (formerly, mevinolin), causes significant reductions
in plasma cholesterol levels. This action can be enhanced by bile acid sequestrants. In ... Cited by 72 - Related articles - All 3 versions
J Kupersmith, M Holmes-Rovner, A Hogan, D … - Progress in cardiovascular …, 1995 - Elsevier Cost-effectiveness analysis of preventive therapies are reviewed in the following categories:
lipid lowering, hypertension, smoking cessation, exercise, and anticoagulation. From review
of 8 analyses, cost-effectiveness of primary prevention via cholesterol lowering drugs is ... Cited by 69 - Related articles - BL Direct - All 5 versions
- ►annals.org RC Pasternak, LE Brown, PH Stone, DI … - Annals of internal …, 1996 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook
Add to Reddit Add to Technorati Add to Twitter What's this? ... Background: Combination drug
therapy has been shown to decrease cholesterol levels in hyperlipidemic patients. ... Cited by 64 - Related articles - BL Direct - All 5 versions
JM Hoeg, HB Brewer Jr - JAMA, 1987 - Am Med Assoc A new class of drugs, which inhibit de novo cholesterol biosynthesis, significantly reduces the
blood cholesterol concentrations in hypercholesterolemic patients. Four separate inhibitors have
lowered plasma total cholesterol and low-density lipoprotein (LDL) levels in humans by ... Cited by 67 - Related articles - All 3 versions
- ►ahajournals.org [PDF] DR Illingworth, S Bacon - Circulation, 1989 - Am Heart Assoc D. Roger Illingworth, MD, PhD, and Sandra Bacon, RN ... We investigated the hypocholesterolemic
effects of lovastatin alone and in combination with ... (LDL) cholesterol decreased from
321+14 mg/dl on diet only to 207+±8 mg/dl (-35.5%) on ... 80 mg/dl (-44.8%, p <0.05 vs. ... Cited by 55 - Related articles - All 5 versions
